Steve Edgett

CEO Consulate General of Canada (CTA Boston)

  • Kanata ON

Steve Edgett has more than 20 years of experience in business development, strategic planning, and international markets.

Contact

Consulate General of Canada (CTA Boston)

View more experts managed by Consulate General of Canada (CTA Boston)

Social

Biography

Steve serves as Genomadix’s CEO after having led the acquisition of Genomadix Bioscience in 2022. Previously, Edgett held the role of Executive Vice President of Genomadix Bioscience where he oversaw corporate strategy and international business development. Steve has more than 20 years of experience in business development, strategic planning, and international markets. He has founded and held senior leadership roles in several high-technology companies, including Knowmadics, Cobham PLC, EMS Technologies and Honeywell International.

Steve holds an Honours Bachelor of Applied Science in Systems Design Engineering from the University of Waterloo.

Industry Expertise

Corporate Leadership
International Trade and Development

Areas of Expertise

Communications Technologies
International Markets
Strategic Planning
New Markets
Business Strategy
Business Development

Education

University of Waterloo

BaSc

Systems Design Engineering

1996

Multimedia

Selected Media Appearances

‘Significant milestone’: FDA approves Genomadix’s rapid genetic-testing device for sale in U.S.

Ottawa Business Journal  online

2023-03-23

CEO Steve Edgett called it a “significant milestone” for Genomadix, which is trying to gain traction after the firm that originally invented the product collapsed amid a failed effort to adapt the device as a rapid COVID-19 test.

View More

Genomadix Announces FDA Clearance to Market Genomadix Cube CYP2C19 System

Yahoo! Finance  online

2023-03-22

"The Genomadix Cube CYP2C19 System empowers physicians to make informed decisions on appropriate drug selection for a number of precision medicine indications such as antiplatelet therapy in both stroke and cardiology patients," said Steve Edgett, Genomadix's Chief Executive Officer. "This achievement represents a milestone for Genomadix. Genomadix is excited to commence precision medicine commercialization activities in the United States."

View More

Ottawa startups remain bullish on fundraising despite headwinds in VC market

Ottawa Business Journal  online

2022-12-08

Chief executive Steve Edgett said the company is polishing up its pitch deck as it prepares to pursue a “proper series-A” round aimed at raising between $25 million and $30 million in the first half of 2023.

“It’s an attractive market,” Edgett says of the current fundraising climate for biotech firms like Genomadix, which makes a rapid COVID-testing device. “There’s quite a bit of money on the sidelines available to finance companies into a growth stage.”

View More

Show All +